Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage

Xencor Inc. (NASDAQ:XNCR) is one of the best high short interest stocks with biggest upside potential. On January 6, Bank of America raised its price target for Xencor to $20 from $17 while maintaining a Neutral rating. This sentiment was announced by the firm as part of its broader update to its US Biopharmaceuticals coverage.

The firm suggested that the biotech sector is experiencing a resurgence driven by several stabilizing factors, including a reward for positive data catalysts, increased large-cap M&A and licensing activity, better access to capital, and a limited impact from drug price regulations. While BofA noted that fundamental pieces are falling into place for the industry, the firm remains cautious regarding the long-term sustainability of this recovery.

Additionally, earlier on December 17, Barclays also raised its price target for Xencor Inc. (NASDAQ:XNCR) from $23 to $26 and maintained an Overweight rating. This decision followed an adjustment of valuations across the biotech sector as part of its 2026 outlook.

Xencor Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer.

While we acknowledge the potential of XNCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.